• IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here.

    The OTHER forum is HERE so please stop asking.

MIT University : USA Now Has Herd Immunity from COVID-19, will Cause Virus to Die Out

capamerica

Alfrescian
Loyal
China Corona Virus Defeated by USA Herd Immunity.

https://www.technologyreview.com/2020/08/11/1006366/immunity-slowing-down-coronavirus-parts-us/


MIT Technology Review


Biotechnology
Population immunity is slowing down the pandemic in parts of the US
The covid-19 pandemic is out of control, but rising infections make it harder to transmit.
by
Disney World guests
OLGA THOMPSON/WALT DISNEY WORLD RESORT
The large number of people already infected with the coronavirus in the US has begun to act as a brake on the spread of the disease in hard-hit states.
Millions of US residents have been infected by the virus that causes covid-19, and at least 160,000 are dead. One effect is that the pool of susceptible individuals has been depleted in many areas. After infection, it’s believed, people become immune (at least for months), so they don’t transmit the virus to others. This slows the pandemic down.
“I believe the substantial epidemics in Arizona, Florida and Texas will leave enough immunity to assist in keeping COVID-19 controlled,” Trevor Bedford, a pandemic analyst at the University of Washington, said on Friday, in a series of tweets. “However, this level of immunity is not compatible with a full return to societal behavior as existed before the pandemic.”
The exact extent to which acquired immunity is slowing the rate of transmission is unknown, but major questions like school reopening and air travel may eventually hinge on the answer.
What is known is that after rising at an alarming pace starting in May, new cases of covid-19 in Sun Belt states like Florida have started to fall. Some of that may be due to social distancing behavior, but rising rates of immunity are also a factor, according to Youyang Gu, a computer scientist whose Covid-19 Projections is among 34 pandemic models tracked by the US Centers for Disease Control and Prevention.
“Immunity may play a significant part in the regions that are declining,” says Gu. At least until the fall, which is how far his models look forward, he says, “I don’t think there is going to be another spike” of infections in southern states.

Herd immunity

The US has been recording more than 1,000 covid-19 deaths and 45,000 confirmed cases a day. The flip side of the rapid spread, however, is there are progressively fewer vulnerable people to catch and spread the virus again. Researchers say they hope to determine how great a role the rise of this population immunity can play in managing the pandemic.
“Clearly, as susceptibility drops, disease spreading drops. No one can say different,” says Tom Britton, a statistician who models the pandemic at the University of Stockholm. “The question is to what degree is the effect because of interventions or because of immunity? In regions with very large outbreaks—New York, Milan, Madrid, and London—I am convinced it’s a combination.”
A virus outbreak will cease to grow, even without any control measures, when a threshold called herd immunity is achieved. That’s when so many people are immune that the virus can’t find new hosts quickly enough.
For the new coronavirus, the threshold for reaching herd immunity is unknown. Estimates vary widely: anywhere from 10% to 80% of the population might have to be infected, depending on how well the virus spreads but also on social factors like how much people ordinarily mix with one another.
Once an obscure inflection point known only to epidemiologists, herd immunity has gained what Francois Balloux, a systems biologist at University College London, calls “Kardashian-like” fame and become a lightning rod in politically polarized debates over economic reopening. On social media, some commenters insist that herd immunity has already arrived, meaning lockdowns and school closures are not necessary. Others find reason to doubt that immunity will ever accumulate without a vaccine and say counting on it can only lead to millions of deaths.
“It seems there is the ‘herd immunity is already reached’ team and the ‘we are all going to die’ team. The good thing is, that there is a third ‘let’s get the data and let’s look at what this all means team’ out there,” tweeted Florian Krammer, an immunologist at the Icahn School of Medicine in New York City.
What is certain is that in the US, with a raging epidemic, natural immunity is building fast. During June and July, Gu estimates, 450,000 people a day were being infected by the coronavirus in the US, the highest figures since the disease arrived in February.
That number is higher than the official case count because it includes an estimate of infections that go unseen, unfelt, or unreported. In June, CDC director Robert Redfield told reporters that the real number of infections could be many times the official tally. For instance, Gu has estimated that about 35 million Americans have now been infected—roughly 10% of the nation’s population.
Natural infection also turns out to be extremely efficient at reducing virus transmission—even more effective than an equal number of people getting a vaccine. The reason is that the virus has been finding and infecting precisely those people who—whether because of behavior, circumstances, or biology—are most likely to be part of transmission chains.
Perhaps they are college students on spring break, or hospital nurses, or people who touch their face all the time. Whatever the reason, once these individuals become infected and are removed from the equation through death or immunity, the effect on the pandemic is outsized. By contrast, vaccinating a sheltered older person might protect that individual but does relatively less to stop transmission.
“When the disease itself causes herd immunity, it does so more efficiently than when we give out vaccine at random,” Marc Lipsitch, a public health modeler at Harvard University, told the political pundit Bill Kristol last week during a podcast interview. As a result, “there is discussion” about whether viral transmission could be reduced more quickly than generally believed, he says.

Lessons from Sweden

Outside the US, researchers are also closely tracking the role of population immunity in national responses. Sweden, for example, did not impose a strict lockdown, and saw a large number of deaths starting in April. Since then, however, the number of new infections has declined. The nation’s leaders said last week that children would go back to school unmasked.
“I would say in Sweden there is no doubt that immunity plays an important role, more than in other countries,” says Britton. “Now this epidemic is slowly stopping.”
Britton says a better understanding of how population immunity is shaping outbreaks could help guide the level and intensity of social interventions. He says the goal is to keep the virus’s reproduction number, called R, below 1, meaning every person with the virus infects fewer than one other. Under those conditions, an outbreak dwindles.
“Herd immunity is when all restrictions can be relaxed and you are still below 1,” he says. “But immunity doesn’t have to be at that level to have an effect.”
In some cities, like New York and Miami, blood tests show that 20% or more of the population has had the virus. But in regions still little affected, like small towns or rural areas, the population remains more susceptible. That means the virus can and will continue to cause new outbreaks. For instance, Louisiana saw a large spike in infections, followed by a lull and then a second spike. This occurred as the virus first hit New Orleans and later reached the rest of the state.
The geographic unevenness of the pandemic is one reason Britton does not think Sweden is able to get back to normal yet. “Are we protected from big outbreaks if all the restrictions are released? The answer is no,” he says. “On a national scale the immunity is not that high—it might be 20%. But in Stockholm it’s maybe 30 or 40%. We may be close to herd immunity [there], so they could relax restrictions a bit more.”
Article meta
Share
Tagged
Author
Antonio Regalado Antonio Regalado
 

kiketerm

Alfrescian
Loyal
hindsight is always 20/20. now the ang moh countries are going to be the winners due to the coming vaccines and natural immunity. losers are those who overreacted.
 

Hypocrite-The

Alfrescian
Loyal
More sensationalism...to keep the fear mongering going

Huge setback for Australia’s hopes
September 9, 2020 10:15am
There are numerous stages of trials and testing to produce a suitable coronavirus vaccine. We take a look at how this is achieved.
The coronavirus vaccine Australia has invested in has been dealt a major setback after researchers uncovered a suspected serious adverse reaction in a trial participant.
The vaccine, being developed by pharmaceutical giant AstraZeneca and the University of Oxford, is being tested at dozens of sites around the world.
The stage 3 trial – the final stage before safety and efficacy data can be submitted to regulators for approval – has tens of thousands of participants.
But the adverse reaction, which AstraZeneca says is an unexplained illness, is believed to have affected a single participant in the UK.
A suspected “serious adverse reaction” means the participant may require hospitalisation. It could result in a life-threatening illness or even death.
Australia has ordered 84 million doses of the AstraZeneca vaccine to be rolled out next year. The Federal Government has signed off on a $1.7 billion supply and production agreement for the vaccine.
undefined
Australia has ordered 84 million doses of the AstraZeneca vaccine. Picture: Bianca De Marchi/NCA NewsWire Source: News Corp Australia
Deputy chief medical officer Nick Coatsworth said reports of a major setback in trials needed to be investigated.
Dr Coatsworth told Today the reported adverse reaction in trials did “not mean that the Oxford vaccine is dead”.
“But it is a serious adverse reaction, and it needs to be investigated,” he said.
Dr Coatsworth said it showed the Oxford vaccine developers were following rigorous safety procedures in reporting the incident.
“The focus on safety is exactly the same and I’m actually taking a lot of reassurance out of these early breaking stories this morning,” he said. “It by no means puts that vaccine completely off the table.”
A spokesman for AstraZeneca, a frontrunner in the race for a COVID-19 vaccine, said in a statement that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
According to medical news website STAT, the nature of the adverse reaction and when it happened were also not known, though the participant is expected to recover.
An AstraZeneca spokesman said the trial pause was done out an “an abundance of caution”.
Dr Nick Coatsworth said the setback needs to be investigated. Picture: David Gray/Getty Images Source: Getty Images
He described the pause as “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials”.
He also said that the company is “working to expedite the review of the single event to minimise any potential impact on the trial timeline”.
Researchers have noticed side effects from the vaccine before, but they have been listed as mild or moderate.
A Phase 1/2 study published in July reported that about 60 per cent of 1000 participants given the vaccine experienced side effects.
All of the side effects, which included fever, headaches, muscle pain and injection site reactions, were deemed mild or moderate. All of the side effects reported also subsided during the course of the study.
Trial holds are not uncommon, but it is a blow to worldwide hopes for a shot to be ready in the coming months, as the AstraZeneca shot was considered by many – including the World Health Organisation (WHO) – to be the leading candidate worldwide.
The Federal Government has signed off on a $1.7 billion supply and production agreement for the vaccine. Picture: Martin Ollman/NCA NewsWire Source: NCA NewsWire
Researchers had hoped to know whether the vaccine worked and was safe by year-end, but that now looks increasingly unlikely.
Just two days ago the Government locked in 84.8 million vaccines at a cost of $1.7 billion, hoping they would be available as early as January 2021.
“There are no guarantees that these vaccines will prove successful, however the agreement puts Australia at the top of the queue if our medical experts give the vaccines the green light,” PM Scott Morrison said this week.
Market confidence in AstraZeneca took a hit as soon as reports of the trial hold emerged.
Shares for AstraZeneca plummeted by eight per cent in after-hours trading.
ABC health expert Norman Swan said the “adverse reaction” could have been unrelated to the vaccine itself as many of the thousands of people taking part are also taking a placebo.
This article contains features which are only available in the web version
“If you’re studying 17,000 people, someone is going to get a heart attack, someone is going
to get pneumonia, somebody is going to break a leg,” he said. “You need to see if it’s attributable to the vaccine.
“The one reaction that scares the vaccine makers is called – it’s an antibody dependent enhancement reaction. It’s really the immune system overreacting when someone gets exposed to the real virus.
“That’s what happened with SARS 1. That’s a fairly recognisable phenomena.
“If it’s something random like a heart attack, it’s unlikely to be anything to be worried about.”
He added that AstraZeneca has done the right thing by pausing the trial.
Dr Coatsworth told Sunrise the Australian Government is investing in multiple technologies and multiple candidates for a COVID vaccine.
“We know not all of them will go to market,” he told Sunrise. “And that’s why we have got so many different vaccines candidates, I believe over 160 around the world, that are being tested.”
The race for a coronavirus vaccine continues. Picture: AFP Source: AFP
As the race for a vaccine continues internationally, AstraZeneca along with eight other major players have pledged to “uphold the integrity of the scientific process”.
It comes amid concern US President Donald Trump will pressure regulators to approve a vaccine ahead of the presidential election in November.
“We, the undersigned biopharmaceutical companies, want to make clear our ongoing commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles,” said the CEOs of the companies in a statement.
The statement was signed by AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi.
– more to come
 

Leongsam

High Order Twit / Low SES subject
Admin
Asset
There is not going to be a vaccine for Covid-19 anytime soon.

The only way to deal with it is to get on with life like the Swedes have done.
 

redbull313

Alfrescian
Loyal
Vaccine? if the AMDKs say its on hold then you can always just take the chink or russia one. they say 100% perfect no problem. u think so u take. i will read about u in paper under obituary section.
 

Hypocrite-The

Alfrescian
Loyal
All the more for the infected to move on instead of being treated.

Coronavirus capable of invading brain: study - The Online Citizen
The Online Citizen

by Issam Ahmed
Headaches, confusion and delirium experienced by some Covid-19 patients could be the result of the coronavirus directly invading the brain, according to a study published Wednesday.
The research is still preliminary — but offers several new lines of evidence to support what was previously a largely untested theory.
According to the paper, which was led by Yale immunologist Akiko Iwasaki, the virus is able to replicate inside the brain, and its presence starves nearby brain cells of oxygen, though the prevalence of this is not yet clear.
S Andrew Josephson, chair of the neurology department at the University of California, San Francisco, praised the techniques used in the study and said “understanding whether or not there is direct viral involvement of the brain is extraordinarily important.”
But he added that he would remain cautious until the paper underwent peer review.
It wouldn’t be completely shocking if SARS-CoV-2 is capable of breaching the blood-brain-barrier, a structure which surrounds the brain’s blood vessels and tries to block foreign substances.
Zika virus, for instance, also does this — leading to significant damage to the brains of fetuses.
But doctors had believed until now that the neurological impacts seen in about half of all patients could instead be the result of an abnormal immune response known as a cytokine storm that causes inflammation of the brain — rather than the virus invading directly.
Prevalence unknown
Iwasaki and colleagues decided to approach the question in three ways: by infecting lab-grown mini-brains known as brain organoids, by infecting mice, and by examining the brain tissues of Covid-19 patients who had died.
In the brain organoids, the team found that the SARS-CoV-2 virus is able to infect neurons and then hijack the neuron cell’s machinery to make copies of itself.
Infected cells in turn promoted the death of surrounding cells by choking their oxygen supply.
One of the main arguments against the theory of direct brain invasion had been that the brain lacks high levels of a protein called ACE2 that the coronavirus latches on to, and which is found in abundance in other organs like the lungs.
But the team found that the organoids had enough ACE2 to facilitate the virus’ entry, and the proteins were also present in the brain tissue of deceased patients.
They also performed a spinal tap on a hospitalized Covid-19 patient suffering from delirium and found the individual had neutralizing antibodies against the virus in their spinal fluid — further evidence in favor of their theory.
The team then looked at two groups of mice — one set that was genetically altered so it had ACE2 receptors in only its lungs, and the other in only its brain.
Those infected in their lungs showed some signs of lung injury, while those infected in the brain lost weight rapidly and quickly died, indicating potentially heightened lethality when the virus enters this organ.
Finally, they examined the brains of three patients who died from severe Covid-19 related complications, finding evidence of the virus in all to varying degrees.
Intriguingly, the infected regions did not show signs of having been infiltrated by immune cells, such as T-cells, which rush to the site of other viruses like Zika or herpes to kill the infected cells.
This could hint that the overloaded immune response known as cytokine storm which is responsible for much of the damage seen in the lungs of Covid-19 patients might not be the main cause of neurological symptoms.
It has been hypothesized that the nose could provide the pathway to the brain, but the authors wrote this needed to be validated through more study.
They added that more autopsies will be required to learn just how prevalent brain infection might be.
– AFP
 

Peiweh

Alfrescian
Loyal
See? What did I tell you people America wins again and again. No wonder it is the king of the world for 75+ years and counting.

cf5661124a142e81a30aaa8a1056ef37.jpg
 
Top